Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 02, 2023

Safety and Efficacy of Dupilumab in Adults With Atopic Dermatitis

Journal of the European Academy of Dermatology and Venereology: JEADV


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the European Academy of Dermatology and Venereology: JEADV
A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis
J Eur Acad Dermatol Venereol 2023 Jan 06;[EPub Ahead of Print], I Vittrup, NS Krogh, HHP Larsen, J Elberling, L Skov, KS Ibler, GBE Jemec, CG Mortz, RO Bach, C Bindslev-Jensen, MG Dalager, A Egeberg, T Agner, M Deleuran, C Vestergaard, JP Thyssen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading